Shaysteh Torkamani-Dordshaikh, Shahram Darabi, Mohsen Norouzian, Reza Bahar, Amirreza Beirami, Meysam Hassani Moghaddam, Mobina Fathi, Kimia Vakili, Foozhan Tahmasebinia, Maryam Bahrami, Hojjat Allah Abbaszadeh, Abbas Aliaghaei
{"title":"探索治疗潜力:Apelin-13 的神经保护作用可促进亨廷顿症大鼠模型的持续运动功能恢复。","authors":"Shaysteh Torkamani-Dordshaikh, Shahram Darabi, Mohsen Norouzian, Reza Bahar, Amirreza Beirami, Meysam Hassani Moghaddam, Mobina Fathi, Kimia Vakili, Foozhan Tahmasebinia, Maryam Bahrami, Hojjat Allah Abbaszadeh, Abbas Aliaghaei","doi":"10.5115/acb.23.284","DOIUrl":null,"url":null,"abstract":"<p><p>Huntington's disease (HD) is a hereditary condition considered by the progressive degeneration of nerve cells in the brain, resultant in motor dysfunction and cognitive impairment. Despite current treatment modalities including pharmaceuticals and various therapies, a definitive cure remains elusive. Therefore, this study investigates the therapeutic potential effect of Apelin-13 in HD management. Thirty male Wistar rats were allocated into three groups: a control group, a group with HD, and a group with both HD and administered Apelin-13. Apelin-13 was administered continuously over a 28-day period at a dosage of around 30 mg/kg to mitigate inflammation in rats subjected to 3-NP injection within an experimental HD model. Behavioral tests, such as rotarod, electromyography (EMG), elevated plus maze, and open field assessments, demonstrated that Apelin-13 improved motor function and coordination in rats injected with 3-NP. Apelin-13 treatment significantly increased neuronal density and decreased glial cell counts compared to the control group. Immunohistochemistry analysis revealed reduced gliosis and expression of inflammatory factors in the treatment group. Moreover, Apelin-13 administration led to elevated levels of glutathione and reduced reactive oxygen species (ROS) level in the treated group. Apelin-13 demonstrates neuroprotective effects, leading to improved movement and reduced inflammatory and fibrotic factors in the HD model.</p>","PeriodicalId":7831,"journal":{"name":"Anatomy & Cell Biology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424562/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.\",\"authors\":\"Shaysteh Torkamani-Dordshaikh, Shahram Darabi, Mohsen Norouzian, Reza Bahar, Amirreza Beirami, Meysam Hassani Moghaddam, Mobina Fathi, Kimia Vakili, Foozhan Tahmasebinia, Maryam Bahrami, Hojjat Allah Abbaszadeh, Abbas Aliaghaei\",\"doi\":\"10.5115/acb.23.284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Huntington's disease (HD) is a hereditary condition considered by the progressive degeneration of nerve cells in the brain, resultant in motor dysfunction and cognitive impairment. Despite current treatment modalities including pharmaceuticals and various therapies, a definitive cure remains elusive. Therefore, this study investigates the therapeutic potential effect of Apelin-13 in HD management. Thirty male Wistar rats were allocated into three groups: a control group, a group with HD, and a group with both HD and administered Apelin-13. Apelin-13 was administered continuously over a 28-day period at a dosage of around 30 mg/kg to mitigate inflammation in rats subjected to 3-NP injection within an experimental HD model. Behavioral tests, such as rotarod, electromyography (EMG), elevated plus maze, and open field assessments, demonstrated that Apelin-13 improved motor function and coordination in rats injected with 3-NP. Apelin-13 treatment significantly increased neuronal density and decreased glial cell counts compared to the control group. Immunohistochemistry analysis revealed reduced gliosis and expression of inflammatory factors in the treatment group. Moreover, Apelin-13 administration led to elevated levels of glutathione and reduced reactive oxygen species (ROS) level in the treated group. Apelin-13 demonstrates neuroprotective effects, leading to improved movement and reduced inflammatory and fibrotic factors in the HD model.</p>\",\"PeriodicalId\":7831,\"journal\":{\"name\":\"Anatomy & Cell Biology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424562/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anatomy & Cell Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5115/acb.23.284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ANATOMY & MORPHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anatomy & Cell Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5115/acb.23.284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ANATOMY & MORPHOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
亨廷顿氏病(Huntington's disease,HD)是一种遗传性疾病,主要表现为大脑神经细胞逐渐退化,导致运动功能障碍和认知障碍。尽管目前的治疗方法包括药物和各种疗法,但仍无法彻底治愈。因此,本研究探讨了 Apelin-13 在 HD 治疗中的潜在疗效。研究人员将 30 只雄性 Wistar 大鼠分为三组:对照组、HD 组和同时患有 HD 和服用 Apelin-13 的组。在为期 28 天的实验中,以每公斤约 30 毫克的剂量连续给大鼠注射 Apelin-13,以减轻在实验性 HD 模型中注射 3-NP 的大鼠的炎症反应。行为测试,如旋转木马、肌电图(EMG)、高架加迷宫和开阔地评估表明,Apelin-13 可改善注射了 3-NP 的大鼠的运动功能和协调性。与对照组相比,Apelin-13 治疗可明显增加神经元密度,减少胶质细胞数量。免疫组化分析显示,治疗组的神经胶质增生和炎症因子表达减少。此外,Apelin-13 还能使治疗组的谷胱甘肽水平升高,活性氧(ROS)水平降低。Apelin-13具有神经保护作用,可改善HD模型的运动,减少炎症和纤维化因子。
Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.
Huntington's disease (HD) is a hereditary condition considered by the progressive degeneration of nerve cells in the brain, resultant in motor dysfunction and cognitive impairment. Despite current treatment modalities including pharmaceuticals and various therapies, a definitive cure remains elusive. Therefore, this study investigates the therapeutic potential effect of Apelin-13 in HD management. Thirty male Wistar rats were allocated into three groups: a control group, a group with HD, and a group with both HD and administered Apelin-13. Apelin-13 was administered continuously over a 28-day period at a dosage of around 30 mg/kg to mitigate inflammation in rats subjected to 3-NP injection within an experimental HD model. Behavioral tests, such as rotarod, electromyography (EMG), elevated plus maze, and open field assessments, demonstrated that Apelin-13 improved motor function and coordination in rats injected with 3-NP. Apelin-13 treatment significantly increased neuronal density and decreased glial cell counts compared to the control group. Immunohistochemistry analysis revealed reduced gliosis and expression of inflammatory factors in the treatment group. Moreover, Apelin-13 administration led to elevated levels of glutathione and reduced reactive oxygen species (ROS) level in the treated group. Apelin-13 demonstrates neuroprotective effects, leading to improved movement and reduced inflammatory and fibrotic factors in the HD model.